Cargando…

Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool asymptomatic testing pilot: population based cohort study

OBJECTIVE: To assess the performance of the SARS-CoV-2 antigen rapid lateral flow test (LFT) versus polymerase chain reaction testing in the asymptomatic general population attending testing centres. DESIGN: Observational cohort study. SETTING: Community LFT pilot at covid-19 testing sites in Liverp...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Fiñana, Marta, Hughes, David M, Cheyne, Christopher P, Burnside, Girvan, Stockbridge, Mark, Fowler, Tom A, Fowler, Veronica L, Wilcox, Mark H, Semple, Malcolm G, Buchan, Iain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259455/
https://www.ncbi.nlm.nih.gov/pubmed/34230058
http://dx.doi.org/10.1136/bmj.n1637
_version_ 1783718671520104448
author García-Fiñana, Marta
Hughes, David M
Cheyne, Christopher P
Burnside, Girvan
Stockbridge, Mark
Fowler, Tom A
Fowler, Veronica L
Wilcox, Mark H
Semple, Malcolm G
Buchan, Iain
author_facet García-Fiñana, Marta
Hughes, David M
Cheyne, Christopher P
Burnside, Girvan
Stockbridge, Mark
Fowler, Tom A
Fowler, Veronica L
Wilcox, Mark H
Semple, Malcolm G
Buchan, Iain
author_sort García-Fiñana, Marta
collection PubMed
description OBJECTIVE: To assess the performance of the SARS-CoV-2 antigen rapid lateral flow test (LFT) versus polymerase chain reaction testing in the asymptomatic general population attending testing centres. DESIGN: Observational cohort study. SETTING: Community LFT pilot at covid-19 testing sites in Liverpool, UK. PARTICIPANTS: 5869 asymptomatic adults (≥18 years) voluntarily attending one of 48 testing sites during 6-29 November 2020. INTERVENTIONS: Participants were tested using both an Innova LFT and a quantitative reverse-transcriptase polymerase chain reaction (RT-qPCR) test based on supervised self-administered swabbing at testing sites. MAIN OUTCOME MEASURES: Sensitivity, specificity, and predictive values of LFT compared with RT-qPCR in an epidemic steady state of covid-19 among adults with no classic symptoms of the disease. RESULTS: Of 5869 test results, 22 (0.4%) LFT results and 343 (5.8%) RT-qPCR results were void (that is, when the control line fails to appear within 30 minutes). Excluding the void results, the LFT versus RT-qPCR showed a sensitivity of 40.0% (95% confidence interval 28.5% to 52.4%; 28/70), specificity of 99.9% (99.8% to 99.99%; 5431/5434), positive predictive value of 90.3% (74.2% to 98.0%; 28/31), and negative predictive value of 99.2% (99.0% to 99.4%; 5431/5473). When the void samples were assumed to be negative, a sensitivity was observed for LFT of 37.8% (26.8% to 49.9%; 28/74), specificity of 99.6% (99.4% to 99.8%; 5431/5452), positive predictive value of 84.8% (68.1% to 94.9%; 28/33), and negative predictive value of 93.4% (92.7% to 94.0%; 5431/5814). The sensitivity in participants with an RT-qPCR cycle threshold (Ct) of <18.3 (approximate viral loads >10(6) RNA copies/mL) was 90.9% (58.7% to 99.8%; 10/11), a Ct of <24.4 (>10(4) RNA copies/mL) was 69.4% (51.9% to 83.7%; 25/36), and a Ct of >24.4 (<10(4) RNA copies/mL) was 9.7% (1.9% to 23.7%; 3/34). LFT is likely to detect at least three fifths and at most 998 in every 1000 people with a positive RT-qPCR test result with high viral load. CONCLUSIONS: The Innova LFT can be useful for identifying infections among adults who report no symptoms of covid-19, particularly those with high viral load who are more likely to infect others. The number of asymptomatic adults with lower Ct (indicating higher viral load) missed by LFT, although small, should be considered when using single LFT in high consequence settings. Clear and accurate communication with the public about how to interpret test results is important, given the chance of missing some cases, even at high viral loads. Further research is needed to understand how infectiousness is reflected in the viral antigen shedding detected by LFT versus the viral loads approximated by RT-qPCR.
format Online
Article
Text
id pubmed-8259455
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-82594552021-07-09 Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool asymptomatic testing pilot: population based cohort study García-Fiñana, Marta Hughes, David M Cheyne, Christopher P Burnside, Girvan Stockbridge, Mark Fowler, Tom A Fowler, Veronica L Wilcox, Mark H Semple, Malcolm G Buchan, Iain BMJ Research OBJECTIVE: To assess the performance of the SARS-CoV-2 antigen rapid lateral flow test (LFT) versus polymerase chain reaction testing in the asymptomatic general population attending testing centres. DESIGN: Observational cohort study. SETTING: Community LFT pilot at covid-19 testing sites in Liverpool, UK. PARTICIPANTS: 5869 asymptomatic adults (≥18 years) voluntarily attending one of 48 testing sites during 6-29 November 2020. INTERVENTIONS: Participants were tested using both an Innova LFT and a quantitative reverse-transcriptase polymerase chain reaction (RT-qPCR) test based on supervised self-administered swabbing at testing sites. MAIN OUTCOME MEASURES: Sensitivity, specificity, and predictive values of LFT compared with RT-qPCR in an epidemic steady state of covid-19 among adults with no classic symptoms of the disease. RESULTS: Of 5869 test results, 22 (0.4%) LFT results and 343 (5.8%) RT-qPCR results were void (that is, when the control line fails to appear within 30 minutes). Excluding the void results, the LFT versus RT-qPCR showed a sensitivity of 40.0% (95% confidence interval 28.5% to 52.4%; 28/70), specificity of 99.9% (99.8% to 99.99%; 5431/5434), positive predictive value of 90.3% (74.2% to 98.0%; 28/31), and negative predictive value of 99.2% (99.0% to 99.4%; 5431/5473). When the void samples were assumed to be negative, a sensitivity was observed for LFT of 37.8% (26.8% to 49.9%; 28/74), specificity of 99.6% (99.4% to 99.8%; 5431/5452), positive predictive value of 84.8% (68.1% to 94.9%; 28/33), and negative predictive value of 93.4% (92.7% to 94.0%; 5431/5814). The sensitivity in participants with an RT-qPCR cycle threshold (Ct) of <18.3 (approximate viral loads >10(6) RNA copies/mL) was 90.9% (58.7% to 99.8%; 10/11), a Ct of <24.4 (>10(4) RNA copies/mL) was 69.4% (51.9% to 83.7%; 25/36), and a Ct of >24.4 (<10(4) RNA copies/mL) was 9.7% (1.9% to 23.7%; 3/34). LFT is likely to detect at least three fifths and at most 998 in every 1000 people with a positive RT-qPCR test result with high viral load. CONCLUSIONS: The Innova LFT can be useful for identifying infections among adults who report no symptoms of covid-19, particularly those with high viral load who are more likely to infect others. The number of asymptomatic adults with lower Ct (indicating higher viral load) missed by LFT, although small, should be considered when using single LFT in high consequence settings. Clear and accurate communication with the public about how to interpret test results is important, given the chance of missing some cases, even at high viral loads. Further research is needed to understand how infectiousness is reflected in the viral antigen shedding detected by LFT versus the viral loads approximated by RT-qPCR. BMJ Publishing Group Ltd. 2021-07-06 /pmc/articles/PMC8259455/ /pubmed/34230058 http://dx.doi.org/10.1136/bmj.n1637 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Research
García-Fiñana, Marta
Hughes, David M
Cheyne, Christopher P
Burnside, Girvan
Stockbridge, Mark
Fowler, Tom A
Fowler, Veronica L
Wilcox, Mark H
Semple, Malcolm G
Buchan, Iain
Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool asymptomatic testing pilot: population based cohort study
title Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool asymptomatic testing pilot: population based cohort study
title_full Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool asymptomatic testing pilot: population based cohort study
title_fullStr Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool asymptomatic testing pilot: population based cohort study
title_full_unstemmed Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool asymptomatic testing pilot: population based cohort study
title_short Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool asymptomatic testing pilot: population based cohort study
title_sort performance of the innova sars-cov-2 antigen rapid lateral flow test in the liverpool asymptomatic testing pilot: population based cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259455/
https://www.ncbi.nlm.nih.gov/pubmed/34230058
http://dx.doi.org/10.1136/bmj.n1637
work_keys_str_mv AT garciafinanamarta performanceoftheinnovasarscov2antigenrapidlateralflowtestintheliverpoolasymptomatictestingpilotpopulationbasedcohortstudy
AT hughesdavidm performanceoftheinnovasarscov2antigenrapidlateralflowtestintheliverpoolasymptomatictestingpilotpopulationbasedcohortstudy
AT cheynechristopherp performanceoftheinnovasarscov2antigenrapidlateralflowtestintheliverpoolasymptomatictestingpilotpopulationbasedcohortstudy
AT burnsidegirvan performanceoftheinnovasarscov2antigenrapidlateralflowtestintheliverpoolasymptomatictestingpilotpopulationbasedcohortstudy
AT stockbridgemark performanceoftheinnovasarscov2antigenrapidlateralflowtestintheliverpoolasymptomatictestingpilotpopulationbasedcohortstudy
AT fowlertoma performanceoftheinnovasarscov2antigenrapidlateralflowtestintheliverpoolasymptomatictestingpilotpopulationbasedcohortstudy
AT fowlerveronical performanceoftheinnovasarscov2antigenrapidlateralflowtestintheliverpoolasymptomatictestingpilotpopulationbasedcohortstudy
AT wilcoxmarkh performanceoftheinnovasarscov2antigenrapidlateralflowtestintheliverpoolasymptomatictestingpilotpopulationbasedcohortstudy
AT semplemalcolmg performanceoftheinnovasarscov2antigenrapidlateralflowtestintheliverpoolasymptomatictestingpilotpopulationbasedcohortstudy
AT buchaniain performanceoftheinnovasarscov2antigenrapidlateralflowtestintheliverpoolasymptomatictestingpilotpopulationbasedcohortstudy